Description: Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders. The Company’s robust portfolio includes several late-stage clinical assets targeting psychiatric and movement disorders, including orphan diseases. Seelos is based in New York, New York.
Home Page: seelostherapeutics.com
SEEL Technical Analysis
300 Park Avenue
New York,
NY
10022
United States
Phone:
646 293 2100
Officers
| Name | Title |
|---|---|
| Dr. Raj Mehra J.D., Ph.D. | Founder, Chairman, CEO & Pres |
| Mr. Michael J. Golembiewski | Chief Financial Officer |
| Ms. Kimberly Farrand | Sr. Director of Clinical Devel. & Operations |
| Mr. Anthony Marciano | Chief Communications Officer |
| Gopal Krishna Ph.D. | Head of Manufacturing & Technical Operations |
| Tim Whitaker M.D. | Chief Medical Officer |
| Ms. Karen Fusaro | Sr. VP & Head of Clinical Operations |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 15.098 |
| Price-to-Sales TTM: | 421.8987 |
| IPO Date: | 1999-04-19 |
| Fiscal Year End: | December |
| Full Time Employees: | 16 |